Neuren Pharmaceuticals Limited (NURPF)
USD 8.0
(14.29%)
USD 8.0
(14.29%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 247.97 Million AUD | 473.12% |
| 2022 | 43.26 Million AUD | 8.02% |
| 2021 | 40.05 Million AUD | 60.53% |
| 2020 | 24.95 Million AUD | 73.21% |
| 2019 | 14.4 Million AUD | -45.93% |
| 2018 | 26.64 Million AUD | 48.47% |
| 2017 | 17.94 Million AUD | 188.95% |
| 2016 | 6.21 Million AUD | -63.26% |
| 2015 | 16.9 Million AUD | -23.53% |
| 2014 | 22.1 Million AUD | -16.31% |
| 2013 | 26.41 Million AUD | 211.41% |
| 2012 | 8.48 Million AUD | -23.84% |
| 2011 | 11.13 Million AUD | 94.79% |
| 2010 | 5.71 Million AUD | -44.41% |
| 2009 | 10.28 Million AUD | 20.37% |
| 2008 | 8.54 Million AUD | -41.42% |
| 2007 | 14.58 Million AUD | -25.29% |
| 2006 | 19.52 Million AUD | -44.54% |
| 2005 | 35.2 Million AUD | 171.6% |
| 2004 | 12.96 Million AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 228.15 Million AUD | 0.0% |
| 2024 Q1 | 228.15 Million AUD | -7.99% |
| 2023 Q1 | 97.52 Million AUD | 125.4% |
| 2023 Q4 | 247.97 Million AUD | 0.0% |
| 2023 Q2 | 97.52 Million AUD | 0.0% |
| 2023 FY | 247.97 Million AUD | 473.12% |
| 2023 Q3 | 247.97 Million AUD | 154.27% |
| 2022 Q4 | 43.26 Million AUD | 0.0% |
| 2022 Q3 | 43.26 Million AUD | 25.09% |
| 2022 FY | 43.26 Million AUD | 8.02% |
| 2022 Q1 | 34.59 Million AUD | -13.65% |
| 2022 Q2 | 34.59 Million AUD | 0.0% |
| 2021 FY | 40.05 Million AUD | 60.53% |
| 2021 Q1 | 18.99 Million AUD | -23.87% |
| 2021 Q2 | 18.99 Million AUD | 0.0% |
| 2021 Q4 | 40.05 Million AUD | 0.0% |
| 2021 Q3 | 40.05 Million AUD | 110.87% |
| 2020 Q4 | 24.95 Million AUD | 0.0% |
| 2020 Q1 | 9.69 Million AUD | -32.71% |
| 2020 Q2 | 9.69 Million AUD | 0.0% |
| 2020 Q3 | 24.95 Million AUD | 157.41% |
| 2020 FY | 24.95 Million AUD | 73.21% |
| 2019 Q1 | 18.09 Million AUD | -32.07% |
| 2019 Q4 | 14.4 Million AUD | 0.0% |
| 2019 Q3 | 14.4 Million AUD | -20.4% |
| 2019 FY | 14.4 Million AUD | -45.93% |
| 2019 Q2 | 18.09 Million AUD | 0.0% |
| 2018 Q3 | 26.64 Million AUD | 41.58% |
| 2018 Q2 | 18.81 Million AUD | 0.0% |
| 2018 Q1 | 18.81 Million AUD | 4.87% |
| 2018 FY | 26.64 Million AUD | 48.47% |
| 2018 Q4 | 26.64 Million AUD | 0.0% |
| 2017 FY | 17.94 Million AUD | 188.95% |
| 2017 Q3 | 17.94 Million AUD | 1059.92% |
| 2017 Q2 | 1.54 Million AUD | 0.0% |
| 2017 Q1 | 1.54 Million AUD | -75.09% |
| 2017 Q4 | 17.94 Million AUD | 0.0% |
| 2016 Q1 | 9.22 Million AUD | -45.44% |
| 2016 FY | 6.21 Million AUD | -63.26% |
| 2016 Q4 | 6.21 Million AUD | 0.0% |
| 2016 Q3 | 6.21 Million AUD | -32.67% |
| 2016 Q2 | 9.22 Million AUD | 0.0% |
| 2015 FY | 16.9 Million AUD | -23.53% |
| 2015 Q4 | 16.9 Million AUD | 0.0% |
| 2015 Q3 | 16.9 Million AUD | -9.73% |
| 2015 Q2 | 18.72 Million AUD | 0.0% |
| 2015 Q1 | 18.72 Million AUD | -15.29% |
| 2014 Q2 | 23.67 Million AUD | 0.0% |
| 2014 FY | 22.1 Million AUD | -16.31% |
| 2014 Q4 | 22.1 Million AUD | 0.0% |
| 2014 Q3 | 22.1 Million AUD | -6.61% |
| 2014 Q1 | 23.67 Million AUD | -10.39% |
| 2013 FY | 26.41 Million AUD | 211.41% |
| 2013 Q1 | 6.59 Million AUD | -22.26% |
| 2013 Q2 | 6.93 Million AUD | 5.17% |
| 2013 Q4 | 26.41 Million AUD | -0.18% |
| 2013 Q3 | 26.46 Million AUD | 281.54% |
| 2012 Q4 | 8.48 Million AUD | 0.0% |
| 2012 FY | 8.48 Million AUD | -23.84% |
| 2011 Q4 | 11.13 Million AUD | 0.0% |
| 2011 FY | 11.13 Million AUD | 94.79% |
| 2010 FY | 5.71 Million AUD | -44.41% |
| 2010 Q4 | 5.71 Million AUD | 0.0% |
| 2009 Q4 | 10.28 Million AUD | 0.0% |
| 2009 FY | 10.28 Million AUD | 20.37% |
| 2008 Q4 | 8.54 Million AUD | 0.0% |
| 2008 FY | 8.54 Million AUD | -41.42% |
| 2007 Q4 | 14.58 Million AUD | 0.0% |
| 2007 FY | 14.58 Million AUD | -25.29% |
| 2006 FY | 19.52 Million AUD | -44.54% |
| 2006 Q4 | 19.52 Million AUD | 0.0% |
| 2005 FY | 35.2 Million AUD | 171.6% |
| 2005 Q4 | 35.2 Million AUD | 0.0% |
| 2004 FY | 12.96 Million AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioxytran, Inc. | 137.63 Thousand USD | -180061.002% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -538.325% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -324663.601% |
| SQZ Biotechnologies Company | 107.18 Million USD | -131.343% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -17215.954% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -2249.536% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -90.437% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -342565.653% |
| Marizyme, Inc. | 22.01 Million USD | -1026.365% |
| Genus plc | 1.02 Billion USD | 75.9% |
| Pharming Group N.V. | 462.85 Million USD | 46.426% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -7384.73% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -49589.503% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -39448.644% |
| ContraFect Corporation | 20.67 Million USD | -1099.139% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -64783.549% |
| IMV Inc. | 31.33 Million USD | -691.382% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -5880.914% |
| ONE Bio Corp. | 70.08 Million USD | -253.811% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -92.958% |
| Mesoblast Limited | 667.9 Million USD | 62.873% |
| MultiCell Technologies, Inc. | 126.22 USD | -196458464.411% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -604.881% |
| Genscript Biotech Corporation | 3.38 Billion USD | 92.677% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -32076.984% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -94806.938% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -3334.601% |
| Biomind Labs Inc. | 73.81 Thousand USD | -335816.228% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -17015.036% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -726.155% |
| Skye Bioscience, Inc. | 11.94 Million USD | -1976.729% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -18155.196% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -8929.124% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -63422.438% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -12563.231% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -35969.098% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -26288.518% |
| EV Biologics, Inc. | 431.71 Thousand USD | -57338.489% |
| Q BioMed Inc. | 3.51 Million USD | -6953.586% |
| GB Sciences, Inc. | 103.44 Thousand USD | -239618.876% |
| Alpha Cognition Inc. | 2.45 Million USD | -10012.268% |
| CSL Limited | 38.02 Billion USD | 99.348% |
| Agentix Corp. | 261.39 Thousand USD | -94765.183% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 44.44% |
| Enzolytics Inc. | 361.7 Million USD | 31.444% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 8.11 Million USD | -2955.699% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -13104.784% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -9425.599% |
| argenx SE | 4.54 Billion USD | 94.541% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -787.382% |
| HST Global, Inc. | 1526.00 USD | -16249572.346% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -419.831% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -24999.016% |
| Halberd Corporation | 10.13 Thousand USD | -2447535.969% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -38666.149% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -2670.876% |
| Zenith Capital Corp. | 7410.00 USD | -3346323.752% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1088394.798% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -76955.742% |
| AVAX Technologies, Inc. | 7.37 Million USD | -3261.322% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -94775.346% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -26622.028% |
| Ember Therapeutics, Inc. | 184.00 USD | -134766204.348% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -398258.18% |
| Helix BioMedix, Inc. | 3.02 Million USD | -8097.122% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -370.522% |
| Kadimastem Ltd | 2.3 Million USD | -10662.213% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -1603.057% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -434218.843% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -10734532.035% |
| LadRx Corporation | 2.3 Million USD | -10644.483% |
| Cell Source, Inc. | 195.17 Thousand USD | -126952.687% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -51500.539% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -70023.891% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -70023.891% |
| Affymax, Inc. | 7.44 Million USD | -3231.587% |
| Mobile Lads Corp. | 52.00 USD | -476865284.615% |
| Itoco Inc. | 1.4 Million USD | -17611.232% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -259128.284% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -233833.962% |
| International Stem Cell Corporation | 5.39 Million USD | -4500.557% |
| CytoDyn Inc. | 11.13 Million USD | -2126.742% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -173339.555% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1386756.823% |
| Qrons Inc. | 420.00 USD | -59040376.19% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -64229.093% |
| SYBLEU INC | 330.46 Thousand USD | -74936.01% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -44812.338% |
| Rebus Holdings, Inc. | 5000.00 USD | -4959300.0% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -60465.871% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -1552.932% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -1395.687% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -313786.076% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -28577.761% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -3198.789% |
| Neutra Corp. | 2851.00 USD | -8697549.947% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -665.198% |
| PureTech Health plc | 693.97 Million USD | 64.268% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -2972.324% |
| IXICO plc | 15.84 Million USD | -1465.082% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -2894.084% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -139.993% |
| CSL Limited | 38.02 Billion USD | 99.348% |
| Cellectis S.A. | 333.99 Million USD | 25.756% |